AI visibility prompts for Pharma and biotech
By Shamil Guliyev · Updated 2026-09-15
Life-science answers are the most conservative of any category: engines cite regulators, trial registries and peer-reviewed literature, and hedge on anything clinical. Visibility work means being present and accurately described in those authoritative sources, and owning the procedural questions — trial participation, access, regulatory pathways — that are legitimate to answer directly.
Who is asking
Several audiences overlap: patients and carers researching a condition or a trial, clinicians checking specifics, and partners or investors assessing a pipeline. All three expect citations to registries and literature, and all three treat unsourced claims as disqualifying.
Prompts by intent
Trials and participation
Procedural prompts that are legitimate to answer and rarely explained plainly.
- How do I find out whether a clinical trial is recruiting for a condition?
- What does participating in a phase II trial actually involve?
- Who is eligible for most oncology trials, and what excludes someone?
- What are the risks and protections for trial participants?
- How long do trial results usually take to be published?
Mechanism and science
Mechanism prompts reward accurate, referenced explanations aimed at non-specialists.
- How do monoclonal antibody therapies work in simple terms?
- What is the difference between a biologic and a small-molecule drug?
- Why do some treatments require refrigeration and others do not?
- How is drug resistance usually explained for antibiotics?
- What does bioavailability mean in practice for patients?
Regulation and approval
Regulatory prompts are precise and heavily cited from official sources.
- What stages does a medicine go through before approval?
- How do EU and US approval pathways differ?
- What is conditional approval and when is it used?
- How are post-marketing safety signals monitored?
- What does orphan designation mean for a treatment?
Access and cost
Access prompts matter most to patients and are poorly served by industry content.
- How are new medicines priced and reimbursed in European systems?
- What patient access schemes typically exist for expensive treatments?
- Why is a treatment available in one country but not another?
- How long after approval does a medicine usually reach patients?
- What support exists for patients who cannot afford a prescribed treatment?
Partnering and investment
B2B prompts with little competition and high commercial value.
- How do pharma partnering deals for early-stage assets usually work?
- What milestones matter most to investors in a preclinical company?
- How is intellectual property typically structured in licensing deals?
- What does a CRO actually take on in a trial programme?
- How do biotech companies plan funding across development stages?
Which engines matter here
Regulators, trial registries and journals carry nearly all citations, and industry pages appear mainly on procedural and partnering questions. Accuracy and sourcing are the entire game here: unsourced claims are ignored, promotional language is stripped, and regulated promotional constraints apply before any editorial consideration.
What a report looks like
Illustrative report card — example output shape, not a customer measurement
| Prompt | Engine | Outcome |
|---|---|---|
| How do I find out whether a trial is recruiting? | ChatGPT Search | Trial registry cited in 3 of 3; company trial page cited in 1 |
| What stages does a medicine go through before approval? | Perplexity Sonar | Regulator pages cited in 3 of 3; no company source used |
| How do pharma partnering deals for early assets work? | Gemini (grounded) | Industry analysis cited in 2 of 3; company page cited in 1 |
Common mistakes
- Publishing clinical claims outside approved promotional constraints — a regulatory problem before an SEO one.
- Describing pipeline assets without registry links, which leaves engines nothing verifiable to cite.
- Ignoring patient-facing procedural content, which is the one area where industry sources are genuinely useful.
Frequently asked questions
- Is AI visibility work appropriate in a regulated industry?
- Yes, within the same constraints as any other communication: accuracy, sourcing and approved claims. The work is making legitimate information findable and quotable, not loosening what may be said.
- What is the highest-value content here?
- Plain-language procedural content — how trials work, how access schemes operate — anchored to registry and regulator links. It is legitimate, useful and almost never written well.
Related industries
Measure your brand now
Your competitors show up in AI answers and you don't? Find out with one audit.
One-off audit from $60. We'll ask for the domain in our reply. Privacy policy
